221 documents

Read All
18:52 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting UGT8 could help treat basal-like breast cancer. In four human basal-like breast cancer cell lines, shRNA targeting UGT8 decreased cancer cell colony formation compared with...
Read More
22:41 , Apr 24, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice with bone-specific overexpression of VEGF-C could be used to screen therapies to treat Gorham-Stout disease. Generation of the model involves crossing a mouse line, in which expression of a tetracycline transactivator...
Read More
19:38 , Mar 10, 2017 |  BC Week In Review  |  Clinical News

Xgeva: Additional Ph III 20090482 data

Additional data from the double-blind, international Phase III 20090482 trial in 1,718 patients with newly diagnosed MM showed that 120 mg subcutaneous Xgeva every 4 weeks led to a median time to first on-study SRE,...
Read More
21:43 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

Xgeva regulatory update

Amgen withdrew an MAA from EMA for Xgeva denosumab seeking to expand the label to include treatment of hypercalcemia of malignancy refractory to IV bisphosphonate therapy. The company said it withdrew the MAA because EMA’s...
Read More
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Chugai, Taisho Pharmaceutical Holdings, Roche sales and marketing update

Chugai and Taisho launched a monthly oral formulation of Boniva ibandronate in Japan to treat osteoporosis. The National Health Insurance (NHI) price of a 100 mg tablet, the recommended monthly dose, is Y2,790 ($25.11). Chugai...
Read More
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

Romosozumab: Additional Phase III data

Additional data from the open-label, international Phase III STRUCTURE trial in 436 postmenopausal women with osteoporosis at high risk for fracture who were previously treated with bisphosphonate therapy showed that once-monthly 210 mg subcutaneous romosozumab...
Read More
08:00 , Mar 7, 2016 |  BioCentury  |  Product Development

Getting hip in osteoporosis

Investors were quick to conclude that Amgen Inc. and UCB Group's romosozumab may be at a disadvantage in the osteoporosis market after the partners reported a miss on non-vertebral fracture rates, and an apparently lower...
Read More
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Boniva ibandronate regulatory update

Chugai and Taisho said Japan approved a monthly oral formulation of Boniva ibandronate to treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho in 2006 to co-develop and...
Read More
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Romosozumab: Phase III data

Top-line data from the open-label, international Phase III STRUCTURE trial in 436 postmenopausal women with osteoporosis at high risk for fracture who were previously treated with bisphosphonate therapy showed that once-monthly 210 mg subcutaneous romosozumab...
Read More
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Boniva ibandronate: Phase III data

The double-blind, Japanese Phase III MOVEST trial in about 400 osteoporosis patients ages >55 showed that 100 mg oral Boniva was non-inferior to IV Bonviva ibandronate on the primary endpoint of the change from baseline...
Read More